Key clinical point: Topical ruxolitinib is a promising treatment for vitiligo, based on 52-week, phase 2 data.
Major finding: After 52 weeks of double-blind topical ruxolitinib cream at the top dose, 58% of vitiligo patients achieved at least a 50% improvement in their facial vitiligo.
Study details: This was a 52-week, double-blind, placebo-controlled, prospective phase 2 clinical trial of 157 vitiligo patients.
Disclosures: The presenter reported receiving research funding from and serving as a consultant to Incyte, the study sponsor. He has similar financial relationships with Pfizer, Aclaris Therapeutics, and the Immune Tolerance Network.
Pandya AG. EADV 2019